Skip to main content
SpringerLink
Log in

The role of hematopoietic growth factors in small cell lung cancer: a review

  • Chapter
Lung Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 72))

  • 122 Accesses

Abstract

Small cell lung cancer (SCLC) is the model of a highly chemosensitive although still noncurable tumor. Very high response rates, including 30% to 50% complete responses, result in a less than 10% long-term disease-free survivalship. Therefore, many attempts have been made in order to optimize the administration of chemotherapy in this setting, but the therapeutic results seem to have reached a plateau roughly one decade ago. The availability of hematopoietic growth factors may offer the opportunity to test new concepts and to define new therapeutic goals with the use of chemotherapy in SCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 429.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 549.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Metcalf D. 1991. Control of granulocytes and macrophages: molecular, cellular and clinical aspects. Science 254:529–533.

    Article  PubMed  CAS  Google Scholar 

  2. Clark SC, Kamen R. 1987. The human hematopoietic colony-stimulating factors. Science 236:1229–1237.

    Article  PubMed  CAS  Google Scholar 

  3. Metcalf D. 1989. Peptide regulatory factors. Lancet i:825–827.

    Article  Google Scholar 

  4. Platzer E. 1989. Human hemopoietic growth factor. Eur J Haematol 42:1–15.

    Article  PubMed  CAS  Google Scholar 

  5. Metcalf D. 1990. The colony stimulating factors. Cancer 65(10):2185–2195.

    Article  PubMed  CAS  Google Scholar 

  6. Demetri GD, Griffin JD. 1991. Granulocyte colony-stimulating factor and its receptor. Blood 78(11):2791–2808.

    PubMed  CAS  Google Scholar 

  7. Cohen AM, Zsebo KM, Inoue H, Hines D, Boone TC, Chazin VR, Tsai L, Rich T, Souza LM. 1987. In vivo stimulation of granulopoiesis by recombinant human granulocyte colony-stimulating factor. Proc Natl Acad Sci USA 84:2484–2488.

    Article  PubMed  CAS  Google Scholar 

  8. Donahue RE, Wang EA, Stone DK, Kamen R, Wong GG, Sehgal PK, Nathan DG, Clark SC. 1986. Stimulation of haematopoiesis in primates by continuous infusion of recombinant GM-CSF. Nature 321:872–875.

    Article  PubMed  CAS  Google Scholar 

  9. Weite K, Bonilla MA, Gillio AP, Boone TC, Potter GK, Gabrilove JL, Moore AS, O’Reilly RJ, Souza LM. 1987. Recombinant human granulocyte colony-stimulating factor. J Exp Med 165:941–948.

    Article  Google Scholar 

  10. Laver J, Moore AS. 1989. Clinical use of recombinant human hematopoietic growth factors. J Natl Cancer 81:1370–1382.

    Article  CAS  Google Scholar 

  11. Devereux S, Linch DC. 1989. Clinical significance of the haemopoietic growth factors. Br J Cancer 59:2–5.

    Article  PubMed  CAS  Google Scholar 

  12. Dührsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. 1988. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72(6):2074–2081.

    PubMed  Google Scholar 

  13. Groopman JE, Mitsuyasu RT, DeLeo MJ, Oette DH, Golde DW. 1987. Effect of recombinant human granulocyte-macrophage colony stimulating factor on myelopoiesis in acquired immunodeficiency syndrom. N Engl J Med 317:593–598.

    Article  PubMed  CAS  Google Scholar 

  14. Kawano Y, Takaue Y, Saito S, Sato J, Shimizu T, Suzue T, Hirao A, Okamoto Y, Abe T, Watanabe T, Kuroda Y, Kimura F, Motoyoshi K, Asano S. 1993. Granulocyte colony-stimulating factor (CSF), macrophage-CFS, granulocyte-macrophage-CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts. Blood 81(3):856–860.

    PubMed  CAS  Google Scholar 

  15. Crawford J, Green MR. 1992. The role of colony stimulating factors as an adjunct to lung cancer chemotherapy: a commentary. Lung Cancer 8:153–158.

    Article  Google Scholar 

  16. Gurney H, Anderson H, Radford J, Potter MR, Swindell R, Steward W, Kamthan A, Chang J, Weiner J, Thatcher N, Crowther D. 1992. Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-simulating factor. Eur J Cancer 28(1):105–112.

    Article  PubMed  CAS  Google Scholar 

  17. Lord BL, Gurney H, Chang J, Thatcher N, Crowther D, Dexter TM. 1993. Haemopoietic cells kinetics in humans treated with rGM-CSF. Int J Cancer 50:26–31.

    Article  Google Scholar 

  18. Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D, Ewen C. 1993. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A(3):319–324.

    Article  PubMed  CAS  Google Scholar 

  19. Furman WL, Fairclough DL, Huhn RD, Pratt CB, Stute N, Petros WP, Evans WE, Bowman LC, Douglass EC, Santana VM, Meyer WH, Crist WM. 1991. Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. J Clin Oncol 9(6):1022–1028.

    PubMed  CAS  Google Scholar 

  20. Groopman JE, Molina JM, Scadden DT. 1989. Hematopoietic growth factors. N Engl J Med 321(21):1449–1459.

    Article  PubMed  CAS  Google Scholar 

  21. Bodey GP, Buckley M, Sathe YS, Freireich EJ. 1966. Quantitative relationships between circulating leucocytes and infection in patients with acute leukemia. Ann Int Med 64(2): 328–340.

    PubMed  CAS  Google Scholar 

  22. Pizzo PA. 1984. Granulocytopenia and cancer therapy. Cancer 54(11):2649–2661.

    Article  PubMed  CAS  Google Scholar 

  23. Morstyn G, Souza LM, Keech J, Sheridan W, Campbell L, Alton NK, Green M, Metcalf D, Fox R. 1988. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet i:667–672.

    Article  Google Scholar 

  24. Morstyn G, Campbell L, Lieschke G, Layton JE, Maher D, O’Connor M, Green M, Sheridan W, Vincent M, Alton K, Souza L, McGrath K, Fox RM. 1989. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 7(10): 1554–1562.

    PubMed  CAS  Google Scholar 

  25. Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistraa SA, Oette D, Whitley M, Frei E, Schnipper LE. 1988. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319(10):593–598.

    Article  PubMed  CAS  Google Scholar 

  26. Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast RC, Gilbert CJ, Oette DH. 1988. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318(14):869–876.

    Article  PubMed  CAS  Google Scholar 

  27. Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, Onetto N, Gillis S, Oette D, Gold M, Buckner D, Hansen JA, Ritz J, Appelbaum FR, Armitage JO, Nadler LM. 1991. Recombinant human GM-CSF after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324:1773–1778.

    Article  PubMed  CAS  Google Scholar 

  28. Sheridan WP, Morstyn G, Wolf M, Dodds A, Lusk J, Maher D, Layton JE, Green MD, Souza L, Fox RM. 1989. Granulocyte colony stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 2:891–895.

    Article  PubMed  CAS  Google Scholar 

  29. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Piler A, Bonadonna G. 1989. Granulocyte-macrophage colony stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 2:580–585.

    Article  PubMed  CAS  Google Scholar 

  30. Sheridan WP, Glenn Begley C, Juttner CA, Szer J, Bik To L, Maher D, McGrath KM, Morstyn G, Fox RM. 1992. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339(14): 640–644.

    Article  PubMed  CAS  Google Scholar 

  31. Radford JA, Ryder WD, Dodwell D, Anderson H, Thatcher N. 1993. Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer 29(1):81–86.

    Article  Google Scholar 

  32. Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM. 1987. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56:809–813.

    Article  PubMed  CAS  Google Scholar 

  33. Morstyn G, Stuart-Harris R, Bishop J, Raghavan D, Kefford R, Lieschke G, Bonnern E, Olver I, Green M, Railings M, Fox R. 1989. Optimal scheduling of granulocyte macrophage colony-stimulating factor (GM-CSF) for the abrogation of chemotherapy induced neutropenia in small cell lung cancer. Proc Am Soc Clin Oncol 8:A850.

    Google Scholar 

  34. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahanda A, Vincent M, Stewart M, Glaspy J. 1991. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 325:164–170.

    Article  PubMed  CAS  Google Scholar 

  35. Masuda N, Fukuoka M, Negoro N, Takada M, Nakagawa K, Kodama N, Kawahara M, Furuse K. 1991. CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 10:A873.

    Google Scholar 

  36. Drings P, Fisher JR. 1990. Biology and clinical use of GM-CSF in lung cancer. Lung 168:1059–1068.

    Article  PubMed  Google Scholar 

  37. Hamm JT, Schiller JH, Oken MM, Gallmeier WM, Rusthoven J, Israel R. 1991. Granulocyte-macrophage colony stimulating factor (GM-CSF) in small cell carcinoma of the lung (SCLC): preliminary analysis of a randomised controlled trial. Proc Am Soc Clin Oncol 10:A878.

    Google Scholar 

  38. Avalos BR, Gasson JC, Hedvat C, Quan SG, Baldwin GC, Weisbart RH, Williams RE, Golde DW, Di Persio JF. 1990. Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. Blood 75(4):851–857.

    PubMed  CAS  Google Scholar 

  39. Baldwin GC, Gasson JC, Kaufman SE, Quan SG, Williams RE, Avalos BR, Gazdar AF, Golde DW, Di Persio JF. 1989. Nonhematopoietic tumor cells express functional GM-CSF receptors. Blood 73(4):1033–1037.

    PubMed  CAS  Google Scholar 

  40. Vellenga E, Biesma B, Meyer C, Wagteveld L, Esselink GE, de Vries E. 1991. The effects of five hematopoietic growth factors on human small cell lung carcinoma cell lines: inter-leukin 3 enhances the proliferation in one of the eleven cell lines. Cancer Res 51:73–76.

    PubMed  CAS  Google Scholar 

  41. Kuwaki T, Hosoi T, Hanazono Y, Tsumura H, Ishikawa F, Miyazono K, Miyagawa K, Takaku F. 1990. Distribution of human granulocyte colony stimulating factor receptors on hematopooietic and non-hematopoietic tumor cell lines. Jpn J Cancer Res 81:560–563.

    Article  PubMed  CAS  Google Scholar 

  42. Suda T, Miura Y, Mizoguchi H, Kubota K, Takaku F. 1980. A case of lung cancer associated with granulocytosis and production of colony-stimulating activity by the tumour. Br J Cancer 41:980–984.

    Article  PubMed  CAS  Google Scholar 

  43. Okabe T, Fujisawa M, Kudo H, Honma H, Ohsawa N, Takkaku F. 1984. Establishment of a human colony-stimulating-factor-producing cell line from an undifferentiated large cell carcinoma of the lung. Cancer 54:1024–1029.

    Article  PubMed  CAS  Google Scholar 

  44. Yamada T, Hirohashi S, Shimosato Y, Kodama T, Hayashi S, Ogura T, Gamou S, Shimizu N. 1985. Giant cell carcinomas of the lung producing colony-stimulating factor in vitro and in vivo. Jpn J Cancer Res 76:967–976.

    PubMed  CAS  Google Scholar 

  45. Nakamura H, Sayami P, Hayata Y. 1992. Analysis of G-CSF producing lung cancer cell lines and non growth stimulatory effects of rhG-CSF on lung cancer cells in vitro and in vivo. Lung Cancer 8:141–152.

    Article  Google Scholar 

  46. Salmon SE, Liu R. 1989. Effects of granulocyte-macrophage colony-stimulating factor on in vitro growth of human solid tumors. J Clin Oncol 7(9): 1346–1350.

    PubMed  CAS  Google Scholar 

  47. Twentyman PR, Wright KA. 1991. Failure of GM-CSF to influence the growth of small cell and non-small cell lung cancer cell lines in vitro. Eur J Cancer 27(1):6–8.

    Article  PubMed  CAS  Google Scholar 

  48. Bunn PA, Crowlet J, Hazuka M, Tolley R, Livingston R. 1992. The role of GM-CSF in limited stage SCLC: A randomized phase III study of the Southwest Oncology Group (SWOG). Proc Am Soc Clin Oncol 11:A974.

    Google Scholar 

  49. Bunn PA Jr, Kelly K. 1993. The role of GM-CSF in lung cancer: a review of the literature. Lung Cancer 9:45–58.

    Article  Google Scholar 

  50. Favaretto A, Paccagnella A, Chiarion Sileni V, Ghiotto C, Comis S, Panozzo M, Ruffato R, Sartore F, Fiorentino MV. 1992. Correlation between GM-CSF administration and dose intensity (DI) of chemotherapy (CT) in SCLC. Proc Am Soc Clin Oncol 11: A1022.

    Google Scholar 

  51. Gabrilove JL, Jakubowski A, Howard Scher PD, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MAS, Clarkson B, Oettgen HF, Alton K, Weite K, Souza L. 1988. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414–1422.

    Article  PubMed  CAS  Google Scholar 

  52. Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentley J, Crowther D. 1992. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 80(6): 1430–1436.

    PubMed  CAS  Google Scholar 

  53. Metha C, Vogl SE. 1982. High-dose cyclophosphamide in the induction chemotherapy of small cell lung cancer: minor improvements in rate of remission and survival. Proc Am Soc Cancer Res 23:A155.

    Google Scholar 

  54. Brower M, Ihde DC, Johnston-Early A, Bunn PA Jr, Cohen MH, Carney DN, Makuch RW, Matthews MJ, Radice PA, Minna JD. 1983. Treatment of extensive stage small cell bronchogenic carcinoma. Effects of variation in intensity of induction therapy. Am J Med 75:993–1000.

    Article  PubMed  CAS  Google Scholar 

  55. Figueredo AT, Hryniuk WM, Strautmanis I, Frank G, Rendells. 1985. Co-trimoxacole prophylaxis during high dose chemotherapy of small cell lung cancer. J Clin Oncol 3(1): 54–64.

    PubMed  CAS  Google Scholar 

  56. Johnson DH, Einhorn LH, Birch R, Vollmer R, Perez C, Krauss S, Omura G, Greco FA, and the Southeastern Cancer Study Group. 1987. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin and vincristin for extensive small cell lung cancer. A phase III trial of the Southern Cancer Study Group. J Clin Oncol 5(11):1731–1738.

    PubMed  CAS  Google Scholar 

  57. Souhami RL, Harper PG, Linch D, Trask C, Goldstone AH, Tobias JS, Spiro SG, Geddes DM, Richards JDM. 1983. High dose cyclophosphamide with autologous marrow transplantation for small cell carcinoma of the bronchus. Cancer Chemother Pharmacol 10:205–207.

    Article  PubMed  CAS  Google Scholar 

  58. Spitzer G, Fahra P, Valdivieso M, Dicke K, Zander A, Vellekoop L, Murphy WK, Dhingra HM, Umsawasdi T, Chiuten D, Carr DT. 1986. High dose intensification therapy with autologous bone marrow support for limited small cell bronchogenic carcinoma. J Clin Oncol 4:4–13.

    PubMed  CAS  Google Scholar 

  59. Humblet Y, Symann M, Bosly A, Delaunois L, Francis C, Machiels J, Beauduin M, Weynants P, Longueville J, Prignot J. 1987. Late intensification chemotherapy with autologous bone marrow transplantation in selected small cell carcinoma of the lung: a randomized study. J Clin Oncol 5:1864–1873.

    PubMed  CAS  Google Scholar 

  60. Luikart SD, Macdonald M, Herzan D, Modeas C, Goutsou M, Clamon G, Maurer G, Perry MC, Green MR. 1991. Ability of daily or twice daily granulocyte-macrophage colony-stimulating factor (GM-CSF) to support dose escalation of etoposide (vp-16) and carboplatin (CBDCA) in extensive small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 10:A825.

    Google Scholar 

  61. Fujita J, Kamei T, Ariyoshi Y, Ikegami H, Furuse K, Fukuoka M. 1993. Dose intensification study of carboplatin and etoposide with G-CSF in small cell lung cancer. Proc Am Soc Clin Oncol 12:A1101.

    Google Scholar 

  62. Masuda N, Fukuoka M, Matsui K, Negoro S, Takada M, Sakai N, Ryu S, Takifuji N, Ito K, Kudoh S, Kusunoki Y. 1990. Evaluation of high dose etoposide combined with cisplatin for treating relapsed small cell lung cancer. Cancer 65:2635–2640.

    Article  PubMed  CAS  Google Scholar 

  63. Shepherd F, Rusthoven J, Goss P, Eisenhauer E. 1991. Phase I–II trial of high dose cisplating, etoposide and GM-CSF for small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 10:A864.

    Google Scholar 

  64. Neidhart J, Stidley C, Ferguson J, Mangalik A, Andersson T, Oldham F. 1990. GM-CSF decreases duration of cytopenia in patients receiving dose intensive therapy with cyclop-hosphamide, etoposide and cisplatin. Proc Am Soc Clin Oncol 9:A753.

    Google Scholar 

  65. Hryniuk WM, Goodyear M. 1990. The calculation of received dose intensity. J Clin Oncol 8:1935–1937.

    PubMed  CAS  Google Scholar 

  66. Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, Dexter TM. 1989. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60:121–125.

    Article  PubMed  CAS  Google Scholar 

  67. Ardizzoni A, Venturini M, Grino L, Sertoli MR, Bruzzi P, Pennucci MC, Mariani GL, Garrone O, Bracarda S, Rosso R, Van Zandwijk N. 1993. High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin — etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer. Eur J Cancer 29(5):687–692.

    Article  Google Scholar 

  68. D’Hondt V, Canon JL, Humblet Y, Weynants P, Duprez P, Beauduin M, Dewitte M, Müll B, Symann M. 1992. Dose-dependant IL3 stimulation of thrombopoiesis and neutropoiesis in patients with small cell lung carcinoma (SCLC) before and after chemotherapy (CT): a placebo-controlled randomized phase II Study. Proc Am Soc Clin Oncol 11:A1321.

    Google Scholar 

  69. Smith JW, Longo DL, Alvord WG, Janik JE, Sharfman WH, Gause BL, Curti BD, Creekmore SP, Holmlund JT, Fenton RG, Sznol M, Miller LL, Shimizu M, Oppenheim JJ, Fiem SJ, Hursey JC, Powers GC, Urba WJ. 1993. The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. N Engl J Med 328:756–751.

    Article  PubMed  Google Scholar 

  70. Ravagnani F, Siena S, Bregni M, Sciorelli G, Gianni AM, Pellegris G. 1990. Large scale collection of ciculating haematopoietic progenitors in cancer patients treated with high dose cyclophosphamide and recombinant human GM-CSF. Eur J Cancer 26(5):562–564.

    Article  PubMed  CAS  Google Scholar 

  71. Leyvraz S, Vuichard P, Grob JP, Scheider P, Ketterer N, von Fliedner V, Lejeune F, Bachmann F. 1993. Multiple sequential high-dose chemotherapy with r-MetHu G-CSF (filgrastim) and infusion of peripheral blood progenitor cells (PBPC) in patients with small cell lung cancer: a feasibility study. Proc Am Soc Clin Oncol 12:A1115.

    Google Scholar 

  72. Eguchi K, Shinkai T, Sasaki Y, Tamura T, Ohe Y, Nakagawa K, Fukuda M, Yamada K, Kojima A, Oshita F, Morita M, Suemasu K, Saijo N. 1990. Subcutaneous administration of recombinant human granulocyte colony-stimulating factor (KRN8601) in intensive chemotherapy for patients with advanced lung cancer. Jpn J Cancer Res 81:1168–1174.

    Article  PubMed  CAS  Google Scholar 

  73. Yoshida T, Nakamura S, Ohtake S, Okafuji K, Kobayashi K, Kondo K, Kanno M, Matano S, Matsuda T, Kanai M, Sugimoto R, Ogawa M, Takaku F. 1990. Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin’s lymphoma. Cancer 66:1904–1909.

    Article  PubMed  CAS  Google Scholar 

  74. Bishop JF, Morstyn G, Stuart-Harris R, Matthews JP, Green M, Zalcberg J, Raghavan D, Fox R, Yuen K, Olver I, Zimet A, Kefford R. 1991. Dose and schedule of granulocyte macrophage colony stimulating factor (GM-CSF) carboplatin and etoposide in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 10:A820.

    Google Scholar 

  75. Appelbaum FR. 1989. The clinical use of haematopoietic growth factors. Semin Hematol 26(Suppl 3):7–14.

    PubMed  CAS  Google Scholar 

  76. De Vries EGE, Biesma B, Willemse Pax HB, Mulder NH, Stern AC, Aalders JG, Vellenga E. 1991. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 51: 116–122.

    PubMed  Google Scholar 

  77. Van Zandwijk N. 1993. The experience of the EORTC Lung Cancer Cooperative Group (abstract). Proc 3rd International conference on small cell lung cancer, Ravenna, Italy, p. 97.

    Google Scholar 

  78. Mayordomo JI, Diaz-Puente MT, Lianes MP, Lopez-Brea M, Lopez E, Paz-Ares L, Hitt R, Alonso S, Sevilla I, Rivas I, Cortes-Funes H. 1993. Decreasing morbidity and cost of treating febrile neutropenia by adding G-CSF and GM-CSF to standard antibiotic therapy: results of a randomized trial. Proc Am Soc Clin Oncol 12:A1510.

    Google Scholar 

  79. Hornung RL, Longo DL. 1992. Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood 80(1):77–83.

    PubMed  CAS  Google Scholar 

  80. Moore MAS. 1992. Does stem cell exhaustion result from combining hematopoietic growth factors with chemotherapy? If so, how do we prevent it? Blood 80(1):3–7.

    PubMed  CAS  Google Scholar 

  81. Thatcher N. 1992. Haematopoietic growth factors and lung cancer treatment. Thorax 47:119–126.

    Article  PubMed  CAS  Google Scholar 

  82. Thomassen MJ, Ahmad M, Barna BP, Antal J, Wiedemann HP, Meeker DP, Klein J, Bauer L, Gibson V, Andresen S, Bukowski RM. 1991. Induction of cytokine messenger RNA and secretion in alveolar macrophages and blood monocytes from patients with lung cancer receiving granulocyte-macrophage colony-stimulating factor therapy. Cancer Res 51:857–862.

    PubMed  CAS  Google Scholar 

  83. Williams D, Park LS. 1991. Hematopoietic effects of a granulocyte-macrophage colony stimulating factor/interleukin 3 fusion protein. Cancer 67(10):2705–2707.

    Article  PubMed  CAS  Google Scholar 

  84. Sekido Y, Takahashi T, Ueda R, Takahashi M, Suzuki H, Nishida K, Tsukamoto T, Hida T, Shimokata K, Zsebo KM, Takaheshi T. 1993. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the C-kit proto oncogene. Cancer Res 53(7):1709–1714.

    PubMed  CAS  Google Scholar 

  85. Mertelsmann R. 1991. Hematopoietins: Biology, pathophysiology and potential as therapeutic agents, Ann Oncol 2:251–263.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Véronique N. Trillet-Lenoir
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Oncology 5074, Rigshospitalet, 9 Blegdamsvej, DK-2100, Copenhagen, Denmark

    Heine H. Hansen

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer Science+Business Media New York

About this chapter

Cite this chapter

Trillet-Lenoir, V.N. (1994). The role of hematopoietic growth factors in small cell lung cancer: a review. In: Hansen, H.H. (eds) Lung Cancer. Cancer Treatment and Research, vol 72. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2630-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2630-8_13

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6128-2

  • Online ISBN: 978-1-4615-2630-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation